Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
131M
-
Number of holders
-
180
-
Total 13F shares, excl. options
-
50M
-
Shares change
-
-853K
-
Total reported value, excl. options
-
$548M
-
Value change
-
+$7.32M
-
Put/Call ratio
-
0.97
-
Number of buys
-
88
-
Number of sells
-
-69
-
Price
-
$10.96
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q1 2023
229 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q1 2023.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 180 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50M shares
of 131M outstanding shares and own 38.24% of the company stock.
Largest 10 shareholders include BlackRock Inc. (7.9M shares), ARMISTICE CAPITAL, LLC (4.17M shares), NEA Management Company, LLC (3.97M shares), STATE STREET CORP (2.58M shares), CITADEL ADVISORS LLC (2.45M shares), Point72 Asset Management, L.P. (1.94M shares), MORGAN STANLEY (1.87M shares), RENAISSANCE TECHNOLOGIES LLC (1.58M shares), GEODE CAPITAL MANAGEMENT, LLC (1.33M shares), and VANGUARD GROUP INC (1.33M shares).
This table shows the top 180 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.